Dure geneesmiddelen * (extramuraal), de vergoeding in 2022
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | ||
|---|---|---|---|---|---|---|
| Rang 2022 |
ATC-code | |||||
| 1 | R07AX32 Ivacaftor met tezacaftor en elexacaftor (Kaftrio ®) | . | . | . | . | 117.093.800 |
| 2 | J06BA02 Immunoglobuline normaal intravasculair (Nanogam ®) | 61.820.000 | 67.401.800 | 72.223.300 | 74.482.700 | 84.186.800 |
| 3 | R07AX02 Ivacaftor (Kalydeco ®) | 10.484.000 | 22.203.000 | 39.515.800 | 37.385.800 | 75.053.000 |
| 4 | C10AX13 Evolocumab (Repatha ®) | 33.398.200 | 39.992.200 | 48.228.100 | 55.537.900 | 66.453.700 |
| 5 | C10AX14 Alirocumab (Praluent ®) | 20.154.800 | 30.221.700 | 41.013.500 | 47.665.500 | 58.353.900 |
| 6 | L04AX07 Dimethylfumaraat (Skilarence ®) | 36.651.100 | 48.706.500 | 51.172.100 | 51.535.400 | 52.610.000 |
| 7 | C09DX04 Valsartan met sacubitril (Entresto ®) | 6.565.300 | 12.007.500 | 19.356.600 | 29.710.400 | 49.495.000 |
| 8 | N04BA02 Levodopa met decarboxylaseremmer (Sinemet ®) | 38.667.100 | 43.358.700 | 44.783.300 | 41.651.300 | 43.634.300 |
| 9 | J05AR20 Emtricitabine met tenofoviralafenamide en bictegravir (Biktarvy ®) | 866.360 | 15.884.800 | 24.907.900 | 28.509.200 | 34.595.400 |
| 10 | L04AD02 Tacrolimus (Prograft ®) | 31.591.500 | 33.212.600 | 33.051.800 | 27.851.900 | 28.974.700 |
| 11 | N07XX08 Tafamidis (Vyndaqel ®) | 2.514.700 | 3.486.900 | 3.879.500 | 3.545.500 | 26.855.300 |
| 12 | A09AA02 Multi-enzymen (lipase protease enz) (Creon ®) | 18.891.800 | 21.110.300 | 22.960.700 | 23.995.300 | 26.770.100 |
| 13 | L04AA27 Fingolimod (Gilenya ®) | 27.140.800 | 27.466.100 | 25.303.800 | 25.289.700 | 23.853.100 |
| 14 | C02KX04 Macitentan (Opsumit ®) | 18.914.600 | 20.323.200 | 22.101.100 | 20.538.500 | 23.724.800 |
| 15 | L01EX09 Nintedanib (Ofev ®) | 9.377.100 | 10.458.000 | 11.985.900 | 17.404.500 | 23.088.000 |
| 16 | H01CB03 Lanreotide (Somatuline ®) | 20.823.000 | 23.342.800 | 25.068.200 | 22.420.300 | 21.726.300 |
| 17 | J05AR18 Emtricitabine tenofovir alafenamide elvitegravir cobicista (Genvoya ®) | 33.761.900 | 31.923.000 | 27.966.100 | 23.652.300 | 21.655.000 |
| 18 | J05AR13 Lamivudine met abacavir en dolutegravir (Triumeq ®) | 35.245.200 | 33.019.900 | 27.020.500 | 20.926.900 | 18.958.000 |
| 19 | J06BA01 Immunoglobuline normaal extravasculair (Cuvitru ®) | 10.940.400 | 13.945.300 | 15.830.500 | 16.638.900 | 18.223.000 |
| 20 | A10BJ02 Liraglutide (Victoza ®) | 13.666.600 | 13.785.300 | 11.632.600 | 9.275.700 | 17.689.100 |
| 21 | J05AR25 Lamivudine met dolutegravir (Dovato ®) | . | 498.670 | 6.201.100 | 11.691.500 | 17.124.100 |
| 22 | B02BX05 Eltrombopag (Revolade ®) | 7.462.900 | 9.773.600 | 11.893.200 | 13.246.000 | 16.664.200 |
| 23 | L04AA31 Teriflunomide (Aubagio ®) | 12.681.800 | 14.052.400 | 15.093.400 | 15.710.200 | 16.279.900 |
| 24 | R07AX30 Ivacaftor met lumacaftor (Orkambi ®) | 89.989.900 | 67.653.000 | 42.097.600 | 37.638.900 | 15.526.100 |
| Totaal | 541.609.060 | 603.827.270 | 643.286.600 | 656.304.300 | 898.587.600 | |